TEK and breast carcinoma: SIRT7 also counteracts metastasis in doxorubicin-resistant breast cancer cells by epigenetically repressing the tyrosine kinase receptor TIE2/TEK via H3K18 deacetylation at its gene promoters, which would otherwise promote migration [149].